Proto Labs, Inc.

PRLB

$80.13

+0.75%

2026-09-04 11:08:05 EDT+$0.60

Industrials

Manufacturing - Miscellaneous

NYSE

Active Trading

Proto Labs, Inc., together with its affiliated companies, functions as a global, e-commerce-driven digital manufacturer, specializing in the rapid creation of custom ...

Price Action of PRLB

$80.13

+0.75%+$0.60

High—

Low—

52W High-13.8%

Rel. vol—

Interval

Range57m

Volume—SMA5SMA10

—

Key Metrics of PRLB

Snapshot

Latest / TTM · 6 periods

Market Cap

$1.92B

ROCE

5.5%

EV / EBITDA

23.27x

+1.8% YoY

FCF Yield

3.3%

-1.6% YoY

Cash Conversion Cycle

55.5d

Current Ratio

3.64

Quick take

Financial Highlights of PRLB

Profitability trend

Latest / TTM · 6 periods

Gross Margin

45.4%

Net Margin

5.4%

P/E Ratio

62.40x

n/a

Debt / Equity

0.00

n/a

Current Ratio

3.64

Dividend Yield

0.0%

Understanding

Calendar of PRLB

Upcoming

Sep 30, 2026In 26 days
Q3 FY2026 · Estimated results
Est. EPS $0.60 · Revenue $149.04M · 3 analysts
Dec 30, 2026
Q4 FY2026 · Estimated results
Est. EPS $0.48 · Revenue $144.75M · 3 analysts

Financial Statements of PRLB

5Y Trend (Revenue, Earnings, FCF)

Metric	Latest	YoYYoY means Year-over-Year. It compares the latest annual value with the previous annual value to show long-term trend strength.	QoQQoQ means Quarter-over-Quarter. It compares the latest quarter with the immediately previous quarter to show short-term momentum changes.
The total money that came through the front door from selling things, before paying a single bill. Think of it as the grand total of every credit card swipe from customers. (YoY compares this year to last year's performance, while QoQ compares the current three months to the previous three).

Insider Transactions of PRLB

Acquisitions (A)

Since May 19, 2026

Disposals (D)

Since May 19, 2026

Monthly shares of acquisitions/disposals with close price trend (shared daily price source)

Earnings Call Transcript of PRLB

1 transcript segments

Q2 2026

Unknown Speaker

Operator: Greetings, and welcome to the Proto Labs Q2 Fiscal Year 2026 Earnings Call. [Operator Instructions] As a reminder, this conference is being recorded. It is now my pleasure to introduce your host, Ryan Johnsrud, Investor Relations. Thank you. You may begin. Ryan Johnsrud: Thank you. Good morning, everyone, and welcome to Proto Labs' Second Quarter 2026 Earnings Conference Call. I am joined today by Suresh Krishna, President and Chief Executive Officer; and Dan Schumacher, Chief Financial Officer. This morning, Proto Labs issued a press release announcing its financial results for the second quarter ended June 30, 2026. The release is available on the company's website as well as an accompanying slide presentation. Our discussion today will include statements relating to future performance and expectations that are or may be considered forward-looking statements and subject to many risks and uncertainties that could cause actual results to differ materially from expectations. Please refer to our earnings press release and recent SEC filings, including our annual report on Form 10-K for information on certain risks that could cause actual outcomes to differ materially and adversely from any forward-looking statements made today. The results and guidance we will discuss include non-GAAP financial measures consistent with our past practice. Please refer to our press release and the accompanying slide presentation at the Investor Relations section of our company website for a complete reconciliation of GAAP to non-GAAP results. And now, I will turn the call over to Suresh Krishna. Suresh? Suresh Krishna: Thank you, Ryan. Good morning, everyone, and thank you for joining our earnings call. We delivered another record quarter with record revenue and strong profitability. As we did in the first quarter, we achieved double-digit revenue growth, gross margin expansion and operating cost leverage. Importantly, our results show that our strategy is beginning to translate into broader business momentum with expanding relationships among larger customers, sustained strength in CNC Machining, meaningful acceleration in Injection Molding and early progress from the changes we are making in Europe. Second quarter revenue per customer grew 17% year-over-year, reflecting continued momentum as we deepen engagement with enterprise accounts. More and more customers are innovating at the speed of software and Proto Labs is the perfect partner to help them rapidly iterate and move from design into production. Strong performance across our factory business reinforces our belief that the investments we are making are gaining traction in the areas where we have our strongest long-term competitive advantages. Injection Molding was a standout performer in the second quarter, growing 13% year-over-year, with strength in telecommunications, driven by data center demand and aerospace and defense. This meaningful acceleration is important because it reflects the …

Leadership Team of PRLB

8 executives

Name	Title	Compensation	Gender	Year Born	Status
Suresh Krishna	President, Chief Executive Officer & Director	USD 974,295	Male	1969	Active
Daniel Schumacher	Chief Financial Officer and Principal Financial & Accounting Officer

Recent News of PRLB

Business Wire8/24/2026Neutral

Protolabs Appoints Sam Ramahi as Chief Operations Officer

MINNEAPOLIS--(BUSINESS WIRE)--Protolabs (NYSE: PRLB), the world's leading provider of digital manufacturing services, today announced the appointment of Sam Ramahi as Chief Operations Officer, effective August 31, 2026. In this role, Ramahi will lead the company's global operations, supply chain, quality, sourcing, and continuous improvement initiatives, reporting to President and Chief Executive Officer Suresh Krishna, who will retain ultimate oversight of Protolabs' operations. Ramahi is expe.

Historical Employee Count of PRLB

Current

2,280

Change

-3.27%

Minimum

2,280

Maximum

2,663

Related stocksManufacturing - Miscellaneous

Browse all US stocks →

About UsPrivacy PolicyTerms of ServiceDisclaimerStock DirectoryETFsIndices13F HoldingsAnalyst TargetsFree ToolsTechnology MapJoin our Slack

Plutux is not an investment adviser. Market data and AI-generated analysis are for information and education only, not investment advice. Disclaimer

Metric	Annual (A vs E)	Annual Surprise	Quarter (A vs E)	Quarter Surprise
EPS Surprise	0.88 vs 1.57	-43.9%	0.37 vs 0.53	-30.2%
Revenue Surprise	$533.1M vs $525.6M	+1.4%	$149.3M vs $144.5M	+3.3%

Report Date	Employees	Form Type	Filing Date	SEC Filing
Dec 31, 2025	2,280	10-K	Feb 20, 2026	View
Dec 31, 2024	2,357	10-K	Feb 21, 2025	View
Dec 31, 2023	2,415	10-K	Feb 16, 2024	View
Dec 31, 2022	2,568	10-K	Feb 21, 2023	View
Dec 31, 2021	2,663	10-K	Feb 18, 2022	View

Date	Executive	Title	Security	Side	Shares	Price
Jun 2, 2026	WEHRWEIN SVEN	director	Common Stock	D	1,500	$76.91
Jun 2, 2026	WEHRWEIN SVEN	director	Common Stock	D	500	$78.38
May 23, 2026	Krishna Suresh	director, officer: President and CEO	Common Stock	D	1,247	$71.36
May 20, 2026	Schumacher Daniel	officer: Chief Financial Officer	Common Stock	D	255	$71.13
May 20, 2026	Parlange Bernardo	officer: Chief Commercial Officer	Employee Stock Option (right to buy)	A	3,789	$71.13

Proto Labs, Inc.

Upcoming

Q3 FY2026 · Estimated results

Q4 FY2026 · Estimated results

Protolabs Appoints Sam Ramahi as Chief Operations Officer

Related stocksManufacturing - Miscellaneous

Upcoming

Q3 FY2026 · Estimated results

Q4 FY2026 · Estimated results

Protolabs Appoints Sam Ramahi as Chief Operations Officer

Here's Why Proto Labs (PRLB) Is a Great 'Buy the Bottom' Stock Now

Proto Labs, Inc. $PRLB Shares Sold by Assenagon Asset Management S.A.

Protolabs Supports MIT Industrial Performance Center Research Fellows to Accelerate U.S. Medical and Aerospace Manufacturing Innovation

Proto Labs (PRLB) Upgraded to Strong Buy: Here's Why

FY2026 · Estimated annual results

Q1 FY2027 · Estimated results

Recent history

Q2 FY2026 · Results reported

Q1 FY2026 · Results reported

FY2025 · Annual results

Q3 FY2025 · Results reported

Q2 FY2025 · Results reported

Q1 FY2025 · Results reported

Recent Filings